Home Cart Sign in  
Chemical Structure| 4192-90-9 Chemical Structure| 4192-90-9

Structure of Trilobatin
CAS No.: 4192-90-9

Chemical Structure| 4192-90-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Trilobatin, a natural product isolated and purified from the herbs of Lithocarpus pachyphyllus with anti-oxidant effect, potentially inhibits the LPS-induced inflammatory response by suppressing the NF-κB signaling pathway and is a potential effective α-glucosidase inhibitor for management of postprandial hyperglycemia with less side effect.

Synonyms: Phloretin-4-O-glucoside; P-Phlorizin; Phloretin-4-O-glucoside, Trilobatin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Trilobatin

CAS No. :4192-90-9
Formula : C21H24O10
M.W : 436.41
SMILES Code : O=C(C1=C(O)C=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C=C1O)CCC3=CC=C(O)C=C3
Synonyms :
Phloretin-4-O-glucoside; P-Phlorizin; Phloretin-4-O-glucoside, Trilobatin
MDL No. :MFCD21333313
InChI Key :GSTCPEBQYSOEHV-QNDFHXLGSA-N
Pubchem ID :6451798

Safety of Trilobatin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary cortical neurons 12.5, 25, 50 µM 24 hours To evaluate the protective effect of Trilobatin on corticosterone-induced neuronal injury. Results showed that Trilobatin concentration-dependently inhibited corticosterone-induced cytotoxicity, restored cell viability, and reduced LDH release. J Agric Food Chem. 2025 Mar 5;73(9):5163-5179
C2C12 myotubes 0.1, 1.0, 10 µM 24 hours Trilobatin prevented palmitate-induced insulin resistance by enhancing glucose uptake and the phosphorylation of IRS1 and AKT, and recovered the translocation of GLUT4 from cytoplasm to membrane. Chin Med. 2020 Oct 12;15:110
Huh 7 cells 0.1, 1.0, 10, 50, 100 µM 24 hours High concentrations of Trilobatin significantly induced the proliferation of Huh 7 cells. Molecules. 2019 Sep 18;24(18):3390
HepG2 cells 50 µM or 100 µM 24 hours High concentrations of Trilobatin significantly induced the proliferation of HepG2 cells. Compared to the control, incubation with 50 or 100 μM trilobatin for 24 h increased the number of viable HepG2 cells by 35% and 50% respectively. Molecules. 2019 Sep 18;24(18):3390
BV2 cells 12.5-50 µM 48 hours TLB concentration-dependently increased cell viability by inhibiting the HMGB1/TLR4/NF-κB signaling pathway Acta Pharmacol Sin. 2022 Oct;43(10):2482-2494
PC12 cells 15, 30, 60 µM 48 hours TLB significantly suppressed H2O2-induced PC12 cell damage by enhancing cell viability, inhibiting mitochondrial membrane potential reduction, and decreasing mitochondrial ROS overgeneration, thereby delaying cell apoptosis. Front Mol Neurosci. 2018 Jul 30;11:267
Hippocampal HT22 cells 12.5, 25, 50 µM 48 hours TLB significantly attenuated Aβ25–35-induced HT22 cell death, as evidenced by MTT assay and LDH release. TLB dramatically mitigated cell death after Aβ25–35 insult via decreasing the intracellular and mitochondrial ROS overproduction and restoring antioxidant enzyme activities, as well as suppressing apoptosis. Front Pharmacol. 2020 May 19;11:584

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
KK-Ay mice Type 2 diabetes model Intragastric administration 10 and 20 mg/kg Twice a day for 28 weeks TLB significantly reduced the high fasting blood glucose level and insulin resistance and promoted the tolerances to exogenous glucose and insulin in KK-Ay mice. Moreover, TLB reduced the content of reactive oxygen species; enhanced antioxidant enzymes activities, including serum catalase, glutathione peroxidase, and superoxide dismutase; and regulated the abnormal parameters of lipid metabolism, including triglyceride, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, and free fatty acid. Front Pharmacol. 2022 Jan 27;13:828473
Ob/ob mice Ob/ob mice (obesity-induced insulin resistance model) Intragastric (i.g.) 10 mg/kg Once daily for 4 weeks Trilobatin significantly improved insulin resistance by decreasing fasting blood glucose and insulin in serum, enhancing the phosphorylation of IRS1 and AKT, and recovering the expression and translocation of GLUT4 in ob/ob mice. Chin Med. 2020 Oct 12;15:110
C57BL/6 mice Diabetic model Intragastric administration 10 mg/kg Single dose, blood glucose measured at 0, 15, 30, 60 and 120 minutes Trilobatin significantly attenuated the intake of glucose in C57BL/6 mice, indicating its activity as an SGLT1/2 inhibitor. Molecules. 2019 Sep 18;24(18):3390
C57BL/6J mice DSS-induced ulcerative colitis model Oral gavage 10, 20, 40 mg/kg Once daily for 5 consecutive days TLB significantly alleviated DSS-induced UC symptoms, including weight loss, colon length shortening, and improvement in histopathological lesions. TLB also reduced proinflammatory cytokines (IL-1β, IL-6, TNF-α) and increased anti-inflammatory cytokines (IL-4, IL-10, IL-22). Adv Sci (Weinh). 2025 Mar;12(10):e2412234
Mice Exhaustive exercise-induced fatigue model Gavage 2.5, 5, 10 mg/kg Twice a day for 28 days TLB alleviates exhaustive exercise-induced fatigue and oxidative stress by mediating the Nrf2/ARE/ferroptosis signaling pathway Front Pharmacol. 2022 Jun 24;13:913367
Sprague-Dawley rats High-fat diet-induced obese rat model Intragastric gavage 30 mg/kg, 60 mg/kg, 120 mg/kg Once daily for four weeks Trilobatin significantly reduced body and liver weight gain induced by a high-fat diet, and the accumulation of perirenal fat, epididymal fat, and brown fat in SD obese rats. Additionally, Trilobatin increased the concentrations of short-chain fatty acids (SCFAs), especially butyrate, and significantly altered the composition of gut microbiota. Nutrients. 2021 Mar 10;13(3):891
Rice Purple rice Foliar spray 30 mg/L Once Exogenous application of Trilobatin significantly increased the total flavonoid content and total antioxidant capacity of purple rice grains Plants (Basel). 2024 Dec 3;13(23):3389
APP/PS1 transgenic mice Alzheimer's disease model Intragastrically 4, 8 mg/kg/day Twice a day for 3 months TLB significantly and dose-dependently ameliorated the cognitive deficits in the two AD animal models Acta Pharmacol Sin. 2022 Oct;43(10):2482-2494
C57BL/6J wild-type mice Chronic unpredictable mild stress (CUMS)-induced depressive-like behavior model Gavage 5, 10, 20 mg/kg Twice daily for 4 weeks To evaluate the alleviative effect of Trilobatin on CUMS-induced depressive-like behavior. Results showed that Trilobatin dose-dependently increased body weight, improved sucrose preference, reduced immobility time, and restored mitochondrial dynamic balance and antioxidant enzyme activities. J Agric Food Chem. 2025 Mar 5;73(9):5163-5179
ICR mice Cisplatin-induced acute kidney injury model Intragastric administration 50 and 100 mg/kg 10 consecutive days TLB significantly reversed the inhibition of CRE, BUN, and MDA levels compared with the cisplatin group and significantly alleviated cisplatin-induced renal pathological changes. TLB alleviated cisplatin-induced nephrotoxicity by regulating the AKT/MAPK signaling pathway and apoptosis. ACS Omega. 2022 Oct 13;7(42):37401-37409
Caenorhabditis elegans Wild-type N2 and various mutant strains Administration via NGM medium 62.5, 125, 250 μM Continuous administration until the end of the experiment TLB significantly extended lifespan, enhanced antioxidant capacity, and acted through the SKN1/SIRT3/DAF16 signaling pathway Front Pharmacol. 2021 Apr 15;12:655045

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.46mL

2.29mL

1.15mL

22.91mL

4.58mL

2.29mL

References

 

Historical Records

Categories